Shares of Histogenics Corp (NASDAQ:HSGX) have been given an average rating of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $2.92.
Several analysts have weighed in on the company. Zacks Investment Research raised Histogenics from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research report on Tuesday, January 15th. ValuEngine cut Histogenics from a “hold” rating to a “sell” rating in a research report on Monday, December 17th. Finally, HC Wainwright cut Histogenics from a “buy” rating to a “neutral” rating in a research report on Monday, December 24th.
In other news, major shareholder Randal J. Kirk sold 998,204 shares of Histogenics stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $0.16, for a total transaction of $159,712.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Randal J. Kirk sold 251,800 shares of Histogenics stock in a transaction that occurred on Friday, January 11th. The shares were sold at an average price of $0.17, for a total transaction of $42,806.00. The disclosure for this sale can be found here. 19.70% of the stock is currently owned by company insiders.
Histogenics stock traded down $0.01 during trading hours on Friday, hitting $0.12. 6,010,176 shares of the stock traded hands, compared to its average volume of 7,354,534. The stock has a market cap of $7.49 million, a price-to-earnings ratio of -0.12 and a beta of 3.52. Histogenics has a one year low of $0.08 and a one year high of $3.05.
Histogenics Company Profile
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.